Exchange: NASDAQ·Updated 07:30 PM EDT
News
all
press releases
Are Medical Stocks Lagging Compugen (CGEN) This Year?
Here is how Compugen (CGEN) and Envoy Medical, Inc. (COCH) have performed compared to their sector so far this year.
Zacks
More News
Compugen (CGEN) Reports Q2 Loss, Misses Revenue Estimates
Compugen (CGEN) delivered earnings and revenue surprises of 0.00% and -3.63%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Compugen Reports Second Quarter 2026 Results
Compugen Reports Second Quarter 2026 Results Compugen Reports Second Quarter 2026 Results PR Newswire HOLON, Israel, Aug. 3, 2026 COM701 MAIA-ovarian trial progressing as planned with median progression-free survival data from the interim analysis expected by Q1 2027Trial-in-progress poster on...
PR Newswire
Compugen to Participate in BTIG Biotechnology Conference 2026
Compugen to Participate in BTIG Biotechnology Conference 2026 Compugen to Participate in BTIG Biotechnology Conference 2026 PR Newswire HOLON, Israel, July 21, 2026 HOLON, Israel, July 21, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company...
PR Newswire
Compugen to Release Second Quarter 2026 Results on Monday, August 3, 2026
Compugen to Release Second Quarter 2026 Results on Monday, August 3, 2026 Compugen to Release Second Quarter 2026 Results on Monday, August 3, 2026 PR Newswire HOLON, Israel, July 20, 2026 HOLON, Israel, July 20, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage...
PR Newswire
Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress
Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress PR Newswire HOLON, Israel, June 18, 2026...
PR Newswire
Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026
Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026 Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026 PR Newswire HOLON, Israel, June 11, 2026 HOLON, Israel, June 11, 2026...
PR Newswire
Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development
Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development PR Newswire HOLON, Israel, June 8, 2026 HOLON, Israel, June 8, 2026 /PRNewswire...
PR Newswire
Compugen Q1 2026 Earnings Call: Complete Transcript
read more...
Benzinga
Compugen Q1 Earnings Call Highlights
Compugen Q1 Earnings Call Highlights...
Yahoo! Finance: News

Advertisement|Remove ads.